Rebecca L Scalzo, Rebecca M Foright, Sara E Hull, Leslie A Knaub, Stevi Johnson-Murguia, Fotobari Kinanee, Jeffrey Kaplan, Julie A Houck, Ginger Johnson, Rachel R Sharp, Austin E Gillen, Kenneth L Jones, Anni M Y Zhang, James D Johnson, Paul S MacLean, Jane E B Reusch, Sabrina Wright-Hobart, Elizabeth A Wellberg
Breast cancer survivors treated with tamoxifen and aromatase inhibitors report weight gain and have an elevated risk of type 2 diabetes, especially if they have obesity. These patient experiences are inconsistent with, preclinical studies using high doses of tamoxifen which reported acute weight loss. We investigated the impact of breast cancer endocrine therapies in a preclinical model of obesity and in a small group of breast adipose tissue samples from women taking tamoxifen to understand the clinical findings...
November 1, 2021: Endocrinology